A Phase 1, Open Label, Non-randomized, Single Center Study to Evaluate the Safety and Immunogenicity of 1 Booster Vaccination With (GVGH Shigella Sonnei 1790GAHB) Vaccine Administered Intramuscularly in Healthy Adults Previously Primed With Three Doses of the Same Vaccine in Study H03_01TP Compared to 1 Vaccination With (1790GAHB) Administered Intramuscularly Either to Subjects Who Received Placebo in the H03_01TP Study or naïve Subjects Who Were Not Part of H03_01TP Study
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Shigella sonnei vaccine (Primary)
- Indications Shigella infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 20 Jun 2017 Planned primary completion date changed from 11 Aug 2017 to 6 Sep 2017.
- 20 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 24 May 2017 Planned End Date changed from 11 Aug 2017 to 6 Sep 2017.